Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Lung-Blood-Pressure drug ease the strain of heart failure?

NCT ID NCT01065454

Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether riociguat, a drug that relaxes blood vessels in the lungs, can safely lower high blood pressure in the lungs of people who also have a weakened left heart chamber. Participants receive either riociguat or a placebo for 16 weeks, with doctors measuring lung artery pressure and oxygen levels via a heart catheter. The goal is to see if the drug improves symptoms and well-being in this specific group of patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
riociguat (Adempas)
What this could lead to
If it works, riociguat could offer a new way to lower blood pressure in the lungs and ease symptoms for people with heart failure-related pulmonary hypertension.
What could go wrong
This is an early-phase trial, so the drug may not prove effective or safe in this specific patient group. Possible side effects include low blood pressure and bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

202 people

The number who actually took part.

Started

Apr 2010

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite optimized heart failure therapy Exclusion Criteria: * Types of pulmonary hypertension other than group 2.1 of Dana Point Classification

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension, pulmonary are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary hypertension Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension, pulmonary Ventricular dysfunction, left

Contacts and locations

Locations

  • Study site

    Los Angeles, California, 90073-1003, United States

  • Study site

    San Diego, California, 92103, United States

  • Study site

    Torrance, California, 90502, United States

  • Study site

    Westminster, California, 92683, United States

  • Study site

    Miami, Florida, 33136, United States

  • Study site

    Iowa City, Iowa, 52242, United States

  • Study site

    Baltimore, Maryland, 21201, United States

  • Study site

    Boston, Massachusetts, 02114-2696, United States

  • Study site

    Rochester, Minnesota, 55905, United States

  • Study site

    St Louis, Missouri, 63110, United States

  • Study site

    Cincinnati, Ohio, 45219, United States

  • Study site

    Fairfield, Ohio, 45014, United States

  • Study site

    Falls Church, Virginia, 22042, United States

  • Study site

    Milwaukee, Wisconsin, 53215, United States

  • Study site

    Sydney, New South Wales, 2010, Australia

  • Study site

    Herston, Queensland, 4029, Australia

  • Study site

    Melbourne, Victoria, 3004, Australia

  • Study site

    Vienna, State of Vienna, 1090, Austria

  • Study site

    Innsbruck, Tyrol, 6020, Austria

  • Study site

    Aalst, 9300, Belgium

  • Study site

    Brussels, 1070, Belgium

  • Study site

    Ghent, 9000, Belgium

  • Study site

    Leuven, 3000, Belgium

  • Study site

    Edmonton, Alberta, T6G 2B7, Canada

  • Study site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Study site

    Montreal, Quebec, H3T 1E2, Canada

  • Study site

    Québec, Quebec, G1V 4G5, Canada

  • Study site

    Beijing, 100020, China

  • Study site

    Shanghai, 200032, China

  • Study site

    Shanghai, 200433, China

  • Study site

    Brno, 656 91, Czechia

  • Study site

    Olomouc, 77900, Czechia

  • Study site

    Prague, 12808, Czechia

  • Study site

    Prague, 140 21, Czechia

  • Study site

    Aarhus N, 8200, Denmark

  • Study site

    Bron, 69677, France

  • Study site

    Lille, 59037, France

  • Study site

    Nantes, 44035, France

  • Study site

    Pessac, 33604, France

  • Study site

    Rouen, 76031, France

  • Study site

    Toulouse, 31059, France

  • Study site

    Heidelberg, Baden-Wurttemberg, 69115, Germany

  • Study site

    Augsburg, Bavaria, 86156, Germany

  • Study site

    Greifswald, Mecklenburg-Vorpommern, 17475, Germany

  • Study site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Study site

    Erfurt, Thuringia, 99089, Germany

  • Study site

    Naples, Campania, 80131, Italy

  • Study site

    Pavia, Lombardy, 27100, Italy

  • Study site

    Nagoya, Aichi-ken, 466-8560, Japan

  • Study site

    Seto, Aichi-ken, 489-8642, Japan

  • Study site

    Ōgaki, Gifu, 503-8502, Japan

  • Study site

    Higashiibaraki, Ibaraki, 311-3193, Japan

  • Study site

    Tsu, Mie-ken, 514-1101, Japan

  • Study site

    Sendai, Miyagi, 980-8574, Japan

  • Study site

    Kita-ku, Osaka, Osaka, 530-8480, Japan

  • Study site

    Osaka, Osaka, 541-8567, Japan

  • Study site

    Suita, Osaka, 565-0871, Japan

  • Study site

    Kusatsu, Shiga, 525-8585, Japan

  • Study site

    Sunto, Shizuoka, 411-8611, Japan

  • Study site

    Arakawa-ku, Tokyo, 116-8567, Japan

  • Study site

    Shinjuku-ku, Tokyo, 162-8666, Japan

  • Study site

    Tanabe, Wakayama, 646-8558, Japan

  • Study site

    Amsterdam, 1081 HV, Netherlands

  • Study site

    Amsterdam, 1091 AC, Netherlands

  • Study site

    Nijmegen, 6525 GA, Netherlands

  • Study site

    Bydgoszcz, 85-168, Poland

  • Study site

    Gdansk, 80-214, Poland

  • Study site

    Warsaw, 04-628, Poland

  • Study site

    Singapore, 119074, Singapore

  • Study site

    Singapore, 169609, Singapore

  • Study site

    Singapore, 308433, Singapore

  • Study site

    A Coruña, A Coruña, 15006, Spain

  • Study site

    Barcelona, Barcelona, 08003, Spain

  • Study site

    Madrid, Madrid, 28041, Spain

  • Study site

    Majadahonda, Madrid, 28222, Spain

  • Study site

    Murcia, Murcia, 30120, Spain

  • Study site

    Palma, Palma de Mallorca, 7198, Spain

  • Study site

    Valencia, Valencia, 46026, Spain

  • Study site

    Geneva, Canton of Geneva, 1205, Switzerland

  • Study site

    Zurich, Canton of Zurich, 8091, Switzerland

  • Study site

    Lugano, Canton Ticino, 6900, Switzerland

  • Study site

    Cambridge, Cambridgeshire, CB2 0AY, United Kingdom

  • Study site

    London, London, SW3 6NP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.